Literature DB >> 33493029

Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: The Heart and Kidney Working Better Together.

Anthony P Carnicelli1, Robert J Mentz1.   

Abstract

Entities:  

Keywords:  Editorials; diabetes mellitus, type 2; heart failure; renal insufficiency, chronic; sodium-glucose transporter 2 inhibitors

Mesh：

Substances：

Year:  2021        PMID： 33493029      PMCID： PMC7850295          DOI： 10.1161/CIRCULATIONAHA.120.052048

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  12 in total

1.  Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association.

Authors:  A C Schoolwerth; D A Sica; B J Ballermann; C S Wilcox
Journal:  Circulation       Date:  2001-10-16       Impact factor: 29.690

2.  Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.

Authors:  Kevin Damman; Mauro Gori; Brian Claggett; Pardeep S Jhund; Michele Senni; Martin P Lefkowitz; Margaret F Prescott; Victor C Shi; Jean L Rouleau; Karl Swedberg; Michael R Zile; Milton Packer; Akshay S Desai; Scott D Solomon; John J V McMurray
Journal:  JACC Heart Fail       Date:  2018-04-11       Impact factor: 12.035

3.  GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials.

Authors:  Lesley A Inker; Hiddo J L Heerspink; Hocine Tighiouart; Andrew S Levey; Josef Coresh; Ron T Gansevoort; Andrew L Simon; Jian Ying; Gerald J Beck; Christoph Wanner; Jürgen Floege; Philip Kam-Tao Li; Vlado Perkovic; Edward F Vonesh; Tom Greene
Journal:  J Am Soc Nephrol       Date:  2019-07-10       Impact factor: 10.121

4.  Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.

Authors:  Andrew S Levey; Ron T Gansevoort; Josef Coresh; Lesley A Inker; Hiddo L Heerspink; Morgan E Grams; Tom Greene; Hocine Tighiouart; Kunihiro Matsushita; Shoshana H Ballew; Yingying Sang; Edward Vonesh; Jian Ying; Tom Manley; Dick de Zeeuw; Kai-Uwe Eckardt; Adeera Levin; Vlado Perkovic; Luxia Zhang; Kerry Willis
Journal:  Am J Kidney Dis       Date:  2019-08-28       Impact factor: 8.860

5.  Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.

Authors:  David Z I Cherney; Bruce A Perkins; Nima Soleymanlou; Maria Maione; Vesta Lai; Alana Lee; Nora M Fagan; Hans J Woerle; Odd Erik Johansen; Uli C Broedl; Maximilian von Eynatten
Journal:  Circulation       Date:  2013-12-13       Impact factor: 29.690

6.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Authors:  Vlado Perkovic; Meg J Jardine; Bruce Neal; Severine Bompoint; Hiddo J L Heerspink; David M Charytan; Robert Edwards; Rajiv Agarwal; George Bakris; Scott Bull; Christopher P Cannon; George Capuano; Pei-Ling Chu; Dick de Zeeuw; Tom Greene; Adeera Levin; Carol Pollock; David C Wheeler; Yshai Yavin; Hong Zhang; Bernard Zinman; Gary Meininger; Barry M Brenner; Kenneth W Mahaffey
Journal:  N Engl J Med       Date:  2019-04-14       Impact factor: 91.245

7.  Dapagliflozin in Patients with Chronic Kidney Disease.

Authors:  Hiddo J L Heerspink; Bergur V Stefánsson; Ricardo Correa-Rotter; Glenn M Chertow; Tom Greene; Fan-Fan Hou; Johannes F E Mann; John J V McMurray; Magnus Lindberg; Peter Rossing; C David Sjöström; Roberto D Toto; Anna-Maria Langkilde; David C Wheeler
Journal:  N Engl J Med       Date:  2020-09-24       Impact factor: 91.245

Review 8.  Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis.

Authors:  Kevin Damman; Mattia A E Valente; Adriaan A Voors; Christopher M O'Connor; Dirk J van Veldhuisen; Hans L Hillege
Journal:  Eur Heart J       Date:  2013-10-27       Impact factor: 29.983

9.  Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.

Authors:  Faiez Zannad; João Pedro Ferreira; Stuart J Pocock; Cordula Zeller; Stefan D Anker; Javed Butler; Gerasimos Filippatos; Sibylle Jenny Hauske; Martina Brueckmann; Egon Pfarr; Janet Schnee; Christoph Wanner; Milton Packer
Journal:  Circulation       Date:  2020-10-23       Impact factor: 29.690

10.  Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.

Authors:  Pardeep S Jhund; Scott D Solomon; Kieran F Docherty; Hiddo J L Heerspink; Inder S Anand; Michael Böhm; Vijay Chopra; Rudolf A de Boer; Akshay S Desai; Junbo Ge; Masafumi Kitakaze; Bela Merkley; Eileen O'Meara; Morten Shou; Sergey Tereshchenko; Subodh Verma; Pham Nguyen Vinh; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Olof Bengtsson; Anna Maria Langkilde; Mikaela Sjöstrand; John J V McMurray
Journal:  Circulation       Date:  2020-10-12       Impact factor: 29.690
View more
  1 in total

Review 1.  Medical management of acute heart failure.

Authors:  Hayaan Kamran; W H Wilson Tang
Journal:  Fac Rev       Date:  2021-12-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.